Pioneer attracted new participation from InvestMichigan! Growth Capital Fund. Previous investors Pharos Capital Group, Highlander Partners, Hopewell Ventures and River Cities Capital Funds also participated in the round.
Thomas Weisel Partners served as the sole financial advisor to Pioneer in connection with the series B financing.
Matthew Songer, Pioneer’s CEO and chairman of the board, said: “This capital will fund our FDA pivotal study for the NuBac nucleus replacement device, enabling us to bring this innovative P3 technology to the US market.”